No published head-to-head randomized trials have compared the safety and efficacy of darolutamide versus apalutamide or enzalutamide in nonmetastatic castration-resistant prostate cancer. This study compares pre-specified adverse events and metastasis-free survival associated with darolutamide vs apalutamide, and darolutamide vs enzalutamide, via matching-adjusted indirect comparisons.